{
  "events": [
    {
      "id": "EVT-2026-001",
      "type": "pdufa",
      "ticker": "AQST",
      "catalyst": "FDA decision on AQST-109 (epinephrine) for emergency treatment of allergic reactions",
      "date": "2026-01-06",
      "date_type": "hard",
      "archetype": "pdufa",
      "status": "completed",
      "notes": "Superseded by Jan 31 PDUFA. FDA identified deficiencies on Jan 9, but review continues for Jan 31 deadline.",
      "linked_idea": null,
      "source": "CatalystAlert PDUFA calendar",
      "discovered_date": "2025-12-30"
    },
    {
      "id": "EVT-2026-002",
      "type": "pdufa",
      "ticker": "TVTX",
      "catalyst": "FDA decision on sparsentan for focal segmental glomerulosclerosis (FSGS)",
      "date": "2026-04-13",
      "date_type": "hard",
      "archetype": "pdufa",
      "status": "tracking",
      "notes": "Priority review, sNDA filing for FSGS indication. IgA nephropathy already approved. FDA extended review to April 13, 2026 (Major Amendment).",
      "linked_idea": null,
      "source": "CatalystAlert PDUFA calendar, BPIQ",
      "discovered_date": "2025-12-30"
    },
    {
      "id": "EVT-2026-003",
      "type": "pdufa",
      "ticker": "AQST",
      "catalyst": "FDA decision on Anaphylm (epinephrine sublingual film) for emergency treatment of anaphylaxis",
      "date": "2026-01-31",
      "date_type": "hard",
      "archetype": "pdufa",
      "status": "tracking",
      "notes": "Priority review. FDA deficiency notice Jan 9; review ongoing. Conditional trade name approval.",
      "linked_idea": null,
      "source": "CatalystAlert PDUFA calendar",
      "discovered_date": "2025-12-30"
    },
    {
      "id": "EVT-2026-004",
      "type": "pdufa",
      "ticker": "ASND",
      "catalyst": "FDA decision on TransCon CNP (navepegritide) for achondroplasia",
      "date": "2026-02-28",
      "date_type": "hard",
      "archetype": "pdufa",
      "status": "tracking",
      "notes": "Rare disease treatment",
      "linked_idea": null,
      "source": "Web search - PDUFA calendar",
      "discovered_date": "2025-12-30"
    },
    {
      "id": "EVT-2026-005",
      "type": "pdufa",
      "ticker": "ALDX",
      "catalyst": "FDA decision on reproxalap for dry eye disease",
      "date": "2026-03-16",
      "date_type": "hard",
      "archetype": "pdufa",
      "status": "tracking",
      "notes": "Extended PDUFA date from original deadline",
      "linked_idea": null,
      "source": "Web search - PDUFA calendar",
      "discovered_date": "2025-12-30"
    },
    {
      "id": "EVT-2026-006",
      "type": "pdufa",
      "ticker": "BMY",
      "catalyst": "FDA decision on deucravacitinib (Sotyktu) for psoriatic arthritis",
      "date": "2026-03-06",
      "date_type": "hard",
      "archetype": "pdufa",
      "status": "tracking",
      "notes": "Label expansion for existing approved drug",
      "linked_idea": null,
      "source": "Web search - PDUFA calendar",
      "discovered_date": "2025-12-30"
    },
    {
      "id": "EVT-2026-007",
      "type": "pdufa",
      "ticker": "GSK",
      "catalyst": "FDA decision on linerixibat for cholestatic pruritus in primary biliary cholangitis",
      "date": "2026-03-24",
      "date_type": "hard",
      "archetype": "pdufa",
      "status": "tracking",
      "notes": "Rare disease indication",
      "linked_idea": null,
      "source": "Web search - PDUFA calendar",
      "discovered_date": "2025-12-30"
    },
    {
      "id": "EVT-2026-008",
      "type": "merger",
      "ticker": "AVDX",
      "catalyst": "Novartis acquisition of Avidity Biosciences expected to close",
      "date": "2026-06-30",
      "date_type": "soft",
      "archetype": "merger_arb",
      "status": "tracking",
      "notes": "$12B acquisition, $72/share (46% premium). Expected close in 2026, exact date TBD",
      "linked_idea": null,
      "source": "FiercePharma M&A coverage",
      "discovered_date": "2025-12-30"
    },
    {
      "id": "EVT-2026-009",
      "type": "merger",
      "ticker": "AKRO",
      "catalyst": "Novo Nordisk acquisition of Akero Therapeutics - COMPLETED",
      "date": "2025-12-09",
      "date_type": "hard",
      "archetype": "merger_arb",
      "status": "completed",
      "notes": "$4.7B acquisition, $54/share + $6 CVR. MASH treatment focus. Deal closed Dec 9, 2025. AKRO delisted, now Novo subsidiary.",
      "linked_idea": null,
      "source": "PwC M&A outlook, Akero IR",
      "discovered_date": "2025-12-30",
      "close_date": "2025-12-09"
    },
    {
      "id": "EVT-2026-010",
      "type": "merger",
      "ticker": "CLRS",
      "catalyst": "Thermo Fisher acquisition of Clario expected to close",
      "date": "2026-06-30",
      "date_type": "soft",
      "archetype": "merger_arb",
      "status": "tracking",
      "notes": "$9.4B acquisition. Expected close early to mid-2026",
      "linked_idea": null,
      "source": "AllianceBernstein M&A analysis",
      "discovered_date": "2025-12-30"
    },
    {
      "id": "EVT-2026-011",
      "type": "merger",
      "ticker": "HALD",
      "catalyst": "Johnson & Johnson acquisition of Halda Therapeutics expected to close",
      "date": "2026-03-31",
      "date_type": "soft",
      "archetype": "merger_arb",
      "status": "tracking",
      "notes": "$3.05B acquisition. Expected close Q1 2026",
      "linked_idea": null,
      "source": "Expert Market Research",
      "discovered_date": "2025-12-30"
    },
    {
      "id": "EVT-2026-012",
      "type": "spinoff",
      "ticker": "CMCSA",
      "catalyst": "Comcast spin-off of Versant Media Group distribution",
      "date": "2026-01-02",
      "date_type": "hard",
      "archetype": "spinoff",
      "status": "completed",
      "notes": "Spinoff completed Jan 2, 2026. Regular-way trading began Jan 5.",
      "linked_idea": null,
      "source": "Comcast investor relations",
      "discovered_date": "2025-12-30"
    },
    {
      "id": "EVT-2026-013",
      "type": "spinoff",
      "ticker": "HON",
      "catalyst": "Honeywell separation of Aerospace and Automation divisions",
      "date": "2026-09-30",
      "date_type": "soft",
      "archetype": "spinoff",
      "status": "tracking",
      "notes": "Projected for second half of 2026. Two separate spinoffs planned",
      "linked_idea": null,
      "source": "StockSpinoffs.com",
      "discovered_date": "2025-12-30"
    },
    {
      "id": "EVT-2026-014",
      "type": "spinoff",
      "ticker": "MIDD",
      "catalyst": "Middleby Corporation spin-off of Industrial Processing Division",
      "date": "2026-03-31",
      "date_type": "soft",
      "archetype": "spinoff",
      "status": "tracking",
      "notes": "Tax-free transaction. Expected completion by early 2026",
      "linked_idea": null,
      "source": "InsideArbitrage spinoff tracker",
      "discovered_date": "2025-12-30"
    },
    {
      "id": "EVT-2026-015",
      "type": "activist",
      "ticker": "NCPL",
      "catalyst": "Strategic EP LLC filed 13D pursuing strategic deal to maximize shareholder value",
      "date": "2025-12-02",
      "date_type": "hard",
      "archetype": "activist",
      "status": "tracking",
      "notes": "Recent 13D filing. Activist pursuing accretive transaction opportunities",
      "linked_idea": null,
      "source": "GlobeNewswire 13D filing announcement",
      "discovered_date": "2025-12-30"
    },
    {
      "id": "EVT-2026-016",
      "type": "pdufa",
      "ticker": "SNY",
      "catalyst": "FDA decision on Cerezyme (imiglucerase) sBLA for Gaucher disease update",
      "date": "2026-01-13",
      "date_type": "hard",
      "archetype": "pdufa",
      "status": "tracking",
      "notes": "Supplemental BLA; lower-volatility label/manufacturing update",
      "linked_idea": null,
      "source": "User report: Event-Driven Alpha: Strategic Catalyst Outlook (H1 2026)",
      "discovered_date": "2025-12-30"
    },
    {
      "id": "EVT-2026-017",
      "type": "pdufa",
      "ticker": "PHAR",
      "catalyst": "FDA decision on leniolisib (Joenja) sNDA for APDS/related immunology expansion",
      "date": "2026-01-31",
      "date_type": "hard",
      "archetype": "pdufa",
      "status": "tracking",
      "notes": "Pharming Group (Euronext: PHAR) label expansion timing cited in report",
      "linked_idea": "PHAR",
      "source": "User report: Event-Driven Alpha: Strategic Catalyst Outlook (H1 2026)",
      "discovered_date": "2025-12-30"
    },
    {
      "id": "EVT-2026-018",
      "type": "pdufa",
      "ticker": "ALNY",
      "catalyst": "FDA decision on Amvuttra (vutrisiran) sNDA for ATTR-CM",
      "date": "2026-03-23",
      "date_type": "hard",
      "archetype": "pdufa",
      "status": "tracking",
      "notes": "HELIOS-B data; potential label expansion into cardiomyopathy",
      "linked_idea": null,
      "source": "User report: Event-Driven Alpha: Strategic Catalyst Outlook (H1 2026)",
      "discovered_date": "2025-12-30"
    },
    {
      "id": "EVT-2026-019",
      "type": "pdufa",
      "ticker": "BIIB",
      "catalyst": "FDA decision on Leqembi subcutaneous formulation for Alzheimer's disease",
      "date": "2026-03-31",
      "date_type": "soft",
      "archetype": "pdufa",
      "status": "tracking",
      "notes": "Targeted for March 2026; Eisai partner",
      "linked_idea": null,
      "source": "User report: Event-Driven Alpha: Strategic Catalyst Outlook (H1 2026)",
      "discovered_date": "2025-12-30"
    },
    {
      "id": "EVT-2026-020",
      "type": "pdufa",
      "ticker": "REPL",
      "catalyst": "FDA decision on RP1 (vusolimogene oderparepvec) for advanced melanoma",
      "date": "2026-04-10",
      "date_type": "hard",
      "archetype": "pdufa",
      "status": "tracking",
      "notes": "Oncolytic virus platform; post-PD-1 refractory setting",
      "linked_idea": null,
      "source": "User report: Event-Driven Alpha: Strategic Catalyst Outlook (H1 2026)",
      "discovered_date": "2025-12-30"
    },
    {
      "id": "EVT-2026-021",
      "type": "pdufa",
      "ticker": "XSPR",
      "catalyst": "FDA decision on XS003 (nilotinib) for chronic myeloid leukemia",
      "date": "2026-06-18",
      "date_type": "hard",
      "archetype": "pdufa",
      "status": "tracking",
      "notes": "505(b)(2) reformulation with improved dosing convenience",
      "linked_idea": null,
      "source": "User report: Event-Driven Alpha: Strategic Catalyst Outlook (H1 2026)",
      "discovered_date": "2025-12-30"
    },
    {
      "id": "EVT-2026-022",
      "type": "spinoff",
      "ticker": "APTV",
      "catalyst": "Aptiv spin-off of Cyprium (EDS wiring business)",
      "date": "2026-03-31",
      "date_type": "soft",
      "archetype": "spinoff",
      "status": "tracking",
      "notes": "Separation of EDS business; expected end of Q1 2026",
      "linked_idea": null,
      "source": "User report: Event-Driven Alpha: Strategic Catalyst Outlook (H1 2026)",
      "discovered_date": "2025-12-30"
    },
    {
      "id": "EVT-2026-023",
      "type": "spinoff",
      "ticker": "SPGI",
      "catalyst": "S&P Global spin-off of Mobility division",
      "date": "2026-06-30",
      "date_type": "soft",
      "archetype": "spinoff",
      "status": "tracking",
      "notes": "Targeted for Q2 2026",
      "linked_idea": null,
      "source": "User report: Event-Driven Alpha: Strategic Catalyst Outlook (H1 2026)",
      "discovered_date": "2025-12-30"
    },
    {
      "id": "EVT-2026-024",
      "type": "spinoff",
      "ticker": "FDX",
      "catalyst": "FedEx spin-off of FedEx Freight",
      "date": "2026-06-30",
      "date_type": "soft",
      "archetype": "spinoff",
      "status": "tracking",
      "notes": "Targeted for June 2026",
      "linked_idea": null,
      "source": "User report: Event-Driven Alpha: Strategic Catalyst Outlook (H1 2026)",
      "discovered_date": "2025-12-30"
    },
    {
      "id": "EVT-2026-025",
      "type": "merger",
      "ticker": "HFWA",
      "catalyst": "Heritage Financial acquisition of Olympic Bancorp expected to close",
      "date": "2026-01-31",
      "date_type": "hard",
      "archetype": "merger_arb",
      "status": "tracking",
      "notes": "Regulatory approval received; targeted close date cited in report",
      "linked_idea": null,
      "source": "User report: Event-Driven Alpha: Strategic Catalyst Outlook (H1 2026)",
      "discovered_date": "2025-12-30"
    },
    {
      "id": "EVT-2026-026",
      "type": "merger",
      "ticker": "OCFC",
      "catalyst": "OceanFirst acquisition of Flushing Financial expected to close",
      "date": "2026-06-30",
      "date_type": "soft",
      "archetype": "merger_arb",
      "status": "tracking",
      "notes": "All-stock merger; targeted for Q2 2026",
      "linked_idea": null,
      "source": "User report: Event-Driven Alpha: Strategic Catalyst Outlook (H1 2026)",
      "discovered_date": "2025-12-30"
    },
    {
      "id": "EVT-2026-027",
      "type": "merger",
      "ticker": "ONTF",
      "catalyst": "Cvent acquisition of ON24 expected to close",
      "date": "2026-06-30",
      "date_type": "soft",
      "archetype": "merger_arb",
      "status": "tracking",
      "notes": "Take-private; targeted for H1 2026",
      "linked_idea": null,
      "source": "User report: Event-Driven Alpha: Strategic Catalyst Outlook (H1 2026)",
      "discovered_date": "2025-12-30"
    },
    {
      "id": "EVT-2026-028",
      "type": "merger",
      "ticker": "SOAR",
      "catalyst": "Volato Group merger with M2i Global expected to close",
      "date": "2026-03-31",
      "date_type": "soft",
      "archetype": "merger_arb",
      "status": "tracking",
      "notes": "Reverse merger; S-4 filed December 2025",
      "linked_idea": null,
      "source": "User report: Event-Driven Alpha: Strategic Catalyst Outlook (H1 2026)",
      "discovered_date": "2025-12-30"
    },
    {
      "id": "EVT-2026-029",
      "type": "activist",
      "ticker": "LUV",
      "catalyst": "Elliott standstill expiration following Southwest settlement",
      "date": "2026-04-01",
      "date_type": "hard",
      "archetype": "activist",
      "status": "tracking",
      "notes": "Standstill expires April 1, 2026; potential renewed activism",
      "linked_idea": null,
      "source": "User report: Event-Driven Alpha: Strategic Catalyst Outlook (H1 2026)",
      "discovered_date": "2025-12-30"
    },
    {
      "id": "EVT-2026-030",
      "type": "activist",
      "ticker": "LULU",
      "catalyst": "Elliott Management $1B stake with CEO replacement proposal",
      "date": "2026-01-02",
      "date_type": "soft",
      "archetype": "activist",
      "status": "tracking",
      "notes": "Tier-1 activist. Elliott acquired $1B+ stake (Dec 18, 2025) and proposed CEO candidate. High-priority campaign targeting leadership change.",
      "linked_idea": "TRD-20260114-LULU-ACTIVIST",
      "source": "CNBC, SEC 13D filing",
      "discovered_date": "2026-01-02",
      "priority": "high",
      "tier": "tier_1"
    },
    {
      "id": "EVT-2026-031",
      "type": "merger",
      "ticker": "CWAN",
      "catalyst": "Permira/Warburg Pincus take-private acquisition at $24.55/share",
      "date": "2026-06-30",
      "date_type": "soft",
      "archetype": "merger_arb",
      "status": "completed",
      "notes": "SUPERSEDED: Starboard activist campaign led to take-private deal. $8.4B acquisition by Permira/Warburg Pincus announced Dec 21, 2025. $24.55/share (47% premium to Nov 10 price). Expected close H1 2026. Go-shop period ended Jan 23, 2026. Spread likely <2.5% (fails merger arb kill screen).",
      "linked_idea": "SUPERSEDED_BY_MERGER",
      "source": "BusinessWire, CNBC",
      "discovered_date": "2026-01-02",
      "priority": "medium",
      "tier": "tier_1",
      "deal_price": 24.55,
      "acquirer": "Permira/Warburg Pincus",
      "outcome": "take_private_announced"
    },
    {
      "id": "EVT-2026-032",
      "type": "activist",
      "ticker": "BILL",
      "catalyst": "Starboard Value 8.5% + Elliott 5%+ stakes in Bill Holdings",
      "date": "2025-12-01",
      "date_type": "soft",
      "archetype": "activist",
      "status": "tracking",
      "notes": "Dual Tier-1 activists. Starboard 8.5% + Elliott 5%+. Cooperation agreement in place (4 new directors). Company exploring strategic alternatives/sale. Investor day H1 2026. Stock down 40% YTD.",
      "linked_idea": "TRD-20260119-BILL-ACTIVIST",
      "source": "Nasdaq, SEC 13D filing, Seeking Alpha",
      "discovered_date": "2026-01-02",
      "priority": "high",
      "tier": "tier_1"
    },
    {
      "id": "EVT-2026-033",
      "type": "pdufa",
      "ticker": "ATRA",
      "catalyst": "FDA decision on tabelecleucel for EBV+ PTLD",
      "date": "2026-01-10",
      "date_type": "hard",
      "archetype": "pdufa",
      "status": "completed",
      "notes": "CRL issued Jan 9, 2026. FDA requested new clinical trial.",
      "linked_idea": null,
      "source": "FDA PDUFA calendar, BPIQ",
      "discovered_date": "2026-01-06",
      "priority": "high"
    },
    {
      "id": "EVT-2026-034",
      "type": "pdufa",
      "ticker": "FBIO",
      "catalyst": "FDA decision on CUTX-101 for Menkes Disease",
      "date": "2026-01-14",
      "date_type": "hard",
      "archetype": "pdufa",
      "status": "completed",
      "notes": "APPROVED Jan 13, 2026 (1 day early). ZYCUBO (copper histidinate) approved as first and only treatment for Menkes disease. Granted Rare Pediatric Disease Voucher. Linked to TRD-20260107-FBIO-PDUFA (closed -9.6% on sell-the-news).",
      "linked_idea": "TRD-20260107-FBIO-PDUFA",
      "source": "FDA PDUFA calendar, Fortress Biotech IR",
      "discovered_date": "2026-01-06",
      "completion_date": "2026-01-13",
      "outcome": "approved"
    },
    {
      "id": "EVT-2026-035",
      "type": "merger",
      "ticker": "OS",
      "catalyst": "Hg acquisition of OneStream",
      "date": "2026-06-30",
      "date_type": "soft",
      "archetype": "merger_arb",
      "status": "tracking",
      "notes": "$6.4B definitive agreement. Expected close H1 2026.",
      "linked_idea": null,
      "source": "PR Newswire, OneStream IR",
      "discovered_date": "2026-01-06"
    },
    {
      "id": "EVT-2026-036",
      "type": "merger",
      "ticker": "CMA",
      "catalyst": "Fifth Third Bancorp acquisition of Comerica Incorporated",
      "date": "2026-03-31",
      "date_type": "soft",
      "archetype": "merger_arb",
      "status": "tracking",
      "notes": "Shareholder approval received. Expected close Q1 2026.",
      "linked_idea": null,
      "source": "Business Wire, SEC filings",
      "discovered_date": "2026-01-06"
    },
    {
      "id": "EVT-2026-037",
      "type": "activist",
      "ticker": "SWX",
      "catalyst": "Icahn Group 8.36% stake in Southwest Gas",
      "date": "2026-01-02",
      "date_type": "hard",
      "archetype": "activist",
      "status": "tracking",
      "notes": "Tier-2 activist (Icahn). Recent 13D/A filing showing increased stake. Teno board resignation Dec 31.",
      "linked_idea": null,
      "source": "SEC 13D filing, StockTitan",
      "discovered_date": "2026-01-06",
      "priority": "high",
      "tier": "tier_2"
    },
    {
      "id": "EVT-2026-038",
      "type": "pdufa",
      "ticker": "RGNX",
      "catalyst": "FDA decision on RGX-121 (clemidsogene) for Hunter Syndrome (MPS II)",
      "date": "2026-02-08",
      "date_type": "hard",
      "archetype": "pdufa",
      "status": "tracking",
      "notes": "First gene therapy for Hunter Syndrome. FDA inspections passed with no objections. Review extended from Nov 2025 to include positive 12-month data. Orphan Drug, Rare Pediatric Disease, Fast Track, RMAT designations. Priority Review Voucher eligible if approved.",
      "linked_idea": "TRD-20260119-RGNX-PDUFA",
      "source": "FDA PDUFA calendar, REGENXBIO IR",
      "discovered_date": "2026-01-06",
      "priority": "high"
    },
    {
      "id": "EVT-2026-039",
      "type": "pdufa",
      "ticker": "SNY",
      "catalyst": "FDA decision on Dupixent (dupilumab) for new indication",
      "date": "2026-02-28",
      "date_type": "hard",
      "archetype": "pdufa",
      "status": "tracking",
      "notes": "Label expansion for chronic spontaneous urticaria (CSU).",
      "linked_idea": null,
      "source": "FDA PDUFA calendar, Sanofi IR",
      "discovered_date": "2026-01-06"
    },
    {
      "id": "EVT-2026-040",
      "type": "merger",
      "ticker": "SNCY",
      "catalyst": "Allegiant Travel Company (ALGT) acquisition of Sun Country Airlines",
      "date": "2026-06-30",
      "date_type": "soft",
      "archetype": "merger_arb",
      "status": "tracking",
      "notes": "Cash and stock deal announced Jan 11, 2026.",
      "linked_idea": null,
      "source": "InsideArbitrage",
      "discovered_date": "2026-01-16"
    },
    {
      "id": "EVT-2026-041",
      "type": "merger",
      "ticker": "VTYX",
      "catalyst": "Eli Lilly acquisition of Ventyx Biosciences",
      "date": "2026-03-31",
      "date_type": "soft",
      "archetype": "merger_arb",
      "status": "tracking",
      "notes": "$1.2B all-cash deal announced Jan 7, 2026.",
      "linked_idea": "PASSED",
      "source": "InsideArbitrage",
      "discovered_date": "2026-01-16"
    },
    {
      "id": "EVT-2026-042",
      "type": "insider",
      "ticker": "YORW",
      "catalyst": "Insider buying cluster for YORW",
      "date": "2026-01-16",
      "date_type": "hard",
      "archetype": "insider",
      "status": "tracking",
      "notes": "Insider cluster: 7 insiders buying between 2026-01-16 and 2026-01-16. Total value approx $15010. Insiders: Becker Suzanne M, Chiaruttini Alexandra C, Grimm Ashley M, Hand Joseph Thomas, Poff Matthew E, Scarpato Matthew J, Snyder Mark S. Titles: CAO, GC, CFO, COO, Pres, CEO, VP- Customer Service, VP- Engineering, VP- HR. Source: http://openinsider.com/latest",
      "linked_idea": null,
      "source": "OpenInsider",
      "discovered_date": "2026-01-16"
    },
    {
      "id": "EVT-2026-043",
      "type": "insider",
      "ticker": "GABC",
      "catalyst": "Insider buying cluster for GABC",
      "date": "2026-01-15",
      "date_type": "hard",
      "archetype": "insider",
      "status": "tracking",
      "notes": "Insider cluster: 3 insiders buying between 2026-01-15 and 2026-01-15. Total value approx $4000. Insiders: Bawel Zachary W, Ellspermann Susan J, Sheidler Jack. Titles: Dir. Source: http://openinsider.com/latest",
      "linked_idea": null,
      "source": "OpenInsider",
      "discovered_date": "2026-01-16"
    },
    {
      "id": "EVT-2026-044",
      "type": "insider",
      "ticker": "NEWT",
      "catalyst": "Insider buying cluster for NEWT",
      "date": "2026-01-14",
      "date_type": "hard",
      "archetype": "insider",
      "status": "tracking",
      "notes": "Insider cluster: 4 insiders buying between 2026-01-14 and 2026-01-14. Total value approx $120405. Insiders: Demaria Frank M, Razon-Feingold Halli, Schwartz Michael Adam, Sloane Barry. Titles: Cheif Financial Officer, GC, Pres, COB, CEO, SVP, HR, CAO. Source: http://openinsider.com/latest",
      "linked_idea": null,
      "source": "OpenInsider",
      "discovered_date": "2026-01-16"
    },
    {
      "id": "EVT-2026-045",
      "type": "merger",
      "ticker": "USB",
      "catalyst": "U.S. Bancorp acquisition of BTIG, LLC",
      "date": "2026-03-31",
      "date_type": "soft",
      "archetype": "merger_arb",
      "status": "tracking",
      "notes": "Definitive agreement announced Jan 12, 2026. Expected close Q1 2026.",
      "linked_idea": null,
      "source": "US Bancorp IR",
      "discovered_date": "2026-01-19"
    },
    {
      "id": "EVT-2026-046",
      "type": "merger",
      "ticker": "BSX",
      "catalyst": "Boston Scientific acquisition of Penumbra, Inc.",
      "date": "2026-06-30",
      "date_type": "soft",
      "archetype": "merger_arb",
      "status": "tracking",
      "notes": "Definitive agreement announced Jan 15, 2026. Major medtech consolidation.",
      "linked_idea": null,
      "source": "Boston Scientific IR",
      "discovered_date": "2026-01-19"
    },
    {
      "id": "EVT-2026-047",
      "type": "merger",
      "ticker": "TDG",
      "catalyst": "TransDigm acquisition of Jet Parts Engineering",
      "date": "2026-03-31",
      "date_type": "soft",
      "archetype": "merger_arb",
      "status": "tracking",
      "notes": "Definitive agreement announced Jan 19, 2026. Aerospace components consolidation.",
      "linked_idea": null,
      "source": "AviTrader",
      "discovered_date": "2026-01-19"
    },
    {
      "id": "EVT-2026-048",
      "type": "activist",
      "ticker": "LVLU",
      "catalyst": "Friedland Enterprises 5% stake in Lulu's Fashion Lounge",
      "date": "2026-01-12",
      "date_type": "hard",
      "archetype": "activist",
      "status": "tracking",
      "notes": "Activist campaign for governance reforms. 13D filed Jan 12, 2026.",
      "linked_idea": "PASSED",
      "source": "SEC 13D filing",
      "discovered_date": "2026-01-19"
    },
    {
      "id": "EVT-2026-049",
      "type": "spinoff",
      "ticker": "KBR",
      "catalyst": "Spin-off of Mission Technology Solutions (MTS)",
      "date": "2026-01-05",
      "date_type": "hard",
      "archetype": "spinoff",
      "status": "completed",
      "notes": "Completed Jan 5. Executive leadership announced.",
      "linked_idea": null,
      "source": "InsideArbitrage",
      "discovered_date": "2026-01-19"
    },
    {
      "id": "EVT-2026-050",
      "type": "spinoff",
      "ticker": "BDX",
      "catalyst": "Merger of Biosciences unit with Waters Corp via Reverse Morris Trust",
      "date": "2026-03-31",
      "date_type": "soft",
      "archetype": "spinoff",
      "status": "tracking",
      "notes": "Complex RMT transaction. Expected Q1 2026.",
      "linked_idea": null,
      "source": "StockSpinoffs",
      "discovered_date": "2026-01-19"
    },
    {
      "id": "EVT-2026-051",
      "type": "insider",
      "ticker": "WRB",
      "catalyst": "Major insider buying by Mitsui Sumitomo",
      "date": "2026-01-15",
      "date_type": "hard",
      "archetype": "insider",
      "status": "active",
      "notes": "1.3M shares / $92M purchase by significant shareholder. High conviction signal.",
      "linked_idea": "TRD-20260119-WRB-INSIDER",
      "source": "SEC Form 4",
      "discovered_date": "2026-01-19"
    },
    {
      "id": "EVT-2026-052",
      "type": "insider",
      "ticker": "TCI",
      "catalyst": "Insider buying cluster: Spencer Davidson",
      "date": "2026-01-15",
      "date_type": "hard",
      "archetype": "insider",
      "status": "tracking",
      "notes": "18 purchases totaling $2M+ in January 2026.",
      "linked_idea": null,
      "source": "QuiverQuant",
      "discovered_date": "2026-01-19"
    },
    {
      "id": "EVT-2026-053",
      "type": "liquidation",
      "ticker": "FRANQ",
      "catalyst": "Francesca's liquidation of all stores",
      "date": "2026-01-31",
      "date_type": "hard",
      "archetype": "liquidation",
      "status": "tracking",
      "notes": "Full chain liquidation. Check for stub value or liquidating trust potential.",
      "linked_idea": "PASSED",
      "source": "Retail Dive",
      "discovered_date": "2026-01-19"
    },
    {
      "id": "EVT-2026-054",
      "type": "legislative",
      "ticker": "USGOV",
      "catalyst": "Consolidated Appropriations Act 2026 (H.R. 6938)",
      "date": "2026-01-15",
      "date_type": "hard",
      "archetype": "legislative",
      "status": "tracking",
      "notes": "Passed Senate Jan 15. Fiscal impact analysis required for sector ETFs.",
      "linked_idea": null,
      "source": "Congress.gov",
      "discovered_date": "2026-01-19"
    },
    {
      "id": "EVT-2026-055",
      "type": "pdufa",
      "ticker": "CODX",
      "catalyst": "FDA Approval of YESINTEK",
      "date": "2026-01-07",
      "date_type": "hard",
      "archetype": "pdufa",
      "status": "completed",
      "notes": "Approved Jan 7, 2026.",
      "linked_idea": null,
      "source": "Google Search",
      "discovered_date": "2026-01-19",
      "outcome": "approved"
    },
    {
      "id": "EVT-2026-056",
      "type": "activist",
      "ticker": "LEN",
      "catalyst": "Gabelli 13D filing pushing for charter changes",
      "date": "2026-01-13",
      "date_type": "hard",
      "archetype": "activist",
      "status": "tracking",
      "notes": "5.49% position reported Jan 13, 2026.",
      "linked_idea": "LEN",
      "source": "SEC 13D filing",
      "discovered_date": "2026-01-19"
    },
    {
      "id": "EVT-2026-057",
      "type": "merger",
      "ticker": "XRPN",
      "catalyst": "SPAC merger with Evernorth",
      "date": "2026-03-31",
      "date_type": "soft",
      "archetype": "merger_arb",
      "status": "tracking",
      "notes": "Digital asset treasury focus. Expected close Q1 2026.",
      "linked_idea": null,
      "source": "Seeking Alpha",
      "discovered_date": "2026-01-19"
    },
    {
      "id": "EVT-2026-058",
      "type": "merger",
      "ticker": "NATH",
      "catalyst": "Smithfield Foods acquisition of Nathan's Famous",
      "date": "2026-06-30",
      "date_type": "soft",
      "archetype": "merger_arb",
      "status": "tracking",
      "notes": "$450M all-cash deal. Announced Jan 21, 2026.",
      "linked_idea": null,
      "source": "InsideArbitrage",
      "discovered_date": "2026-01-22"
    },
    {
      "id": "EVT-2026-059",
      "type": "merger",
      "ticker": "RAPT",
      "catalyst": "GSK acquisition of RAPT Therapeutics",
      "date": "2026-06-30",
      "date_type": "soft",
      "archetype": "merger_arb",
      "status": "tracking",
      "notes": "$1.9B definitive agreement. Announced Jan 20, 2026.",
      "linked_idea": null,
      "source": "InsideArbitrage",
      "discovered_date": "2026-01-22"
    },
    {
      "id": "EVT-2026-060",
      "type": "merger",
      "ticker": "CVGW",
      "catalyst": "Mission Produce acquisition of Calavo Growers",
      "date": "2026-06-30",
      "date_type": "soft",
      "archetype": "merger_arb",
      "status": "tracking",
      "notes": "$430M cash and stock deal. Announced Jan 14, 2026.",
      "linked_idea": null,
      "source": "InsideArbitrage",
      "discovered_date": "2026-01-22"
    },
    {
      "id": "EVT-2026-061",
      "type": "activist",
      "ticker": "HCAT",
      "catalyst": "Whetstone Capital Advisors 7.4% stake in Health Catalyst",
      "date": "2026-01-21",
      "date_type": "hard",
      "archetype": "activist",
      "status": "tracking",
      "notes": "Activist 13D filing. Proposing governance changes (board declassification).",
      "linked_idea": null,
      "source": "StockTitan, SEC 13D",
      "discovered_date": "2026-01-22",
      "priority": "high"
    },
    {
      "id": "EVT-2026-062",
      "type": "activist",
      "ticker": "MIGI",
      "catalyst": "Endeavor Blockchain 44.9% stake in Mawson Infrastructure Group",
      "date": "2026-01-21",
      "date_type": "hard",
      "archetype": "activist",
      "status": "tracking",
      "notes": "Large activist stake. Discussions on value creation and capital structure.",
      "linked_idea": null,
      "source": "StockTitan, SEC 13D/A",
      "discovered_date": "2026-01-22"
    },
    {
      "id": "EVT-2026-063",
      "type": "pdufa",
      "ticker": "CRNX",
      "catalyst": "FDA decision on paltusotine for acromegaly",
      "date": "2026-02-28",
      "date_type": "hard",
      "archetype": "pdufa",
      "status": "tracking",
      "notes": "PDUFA date Feb 28, 2026. Rare disease indication.",
      "linked_idea": null,
      "source": "GoodRx, CatalystAlert",
      "discovered_date": "2026-01-22"
    },
    {
      "id": "EVT-2026-064",
      "type": "pdufa",
      "ticker": "ASND",
      "catalyst": "FDA decision on TransCon hGH (navepegritide) for achondroplasia",
      "date": "2026-02-25",
      "date_type": "hard",
      "archetype": "pdufa",
      "status": "tracking",
      "notes": "PDUFA date Feb 25, 2026.",
      "linked_idea": null,
      "source": "CatalystAlert",
      "discovered_date": "2026-01-22"
    },
    {
      "id": "EVT-2026-065",
      "type": "pdufa",
      "ticker": "PGEN",
      "catalyst": "FDA decision on PRGN-3005 for ovarian cancer",
      "date": "2026-02-26",
      "date_type": "hard",
      "archetype": "pdufa",
      "status": "tracking",
      "notes": "Priority Review. PDUFA date Feb 26, 2026.",
      "linked_idea": null,
      "source": "CatalystAlert",
      "discovered_date": "2026-01-22"
    },
    {
      "id": "EVT-2026-066",
      "type": "pdufa",
      "ticker": "LLY",
      "catalyst": "FDA decision on orforglipron (GLP-1) for weight loss",
      "date": "2026-03-31",
      "date_type": "soft",
      "archetype": "pdufa",
      "status": "tracking",
      "notes": "Expected March 2026. High-profile weight loss drug.",
      "linked_idea": null,
      "source": "PharmaVoice",
      "discovered_date": "2026-01-22"
    },
    {
      "id": "EVT-2026-067",
      "type": "pdufa",
      "ticker": "JAZZ",
      "catalyst": "FDA decision on JZP-458 (Rylaze) label expansion",
      "date": "2026-03-28",
      "date_type": "hard",
      "archetype": "pdufa",
      "status": "tracking",
      "notes": "Priority Review. PDUFA date March 28, 2026.",
      "linked_idea": null,
      "source": "CatalystAlert",
      "discovered_date": "2026-01-22"
    },
    {
      "id": "EVT-2026-068",
      "type": "insider",
      "ticker": "MU",
      "catalyst": "Insider buying cluster: Micron",
      "date": "2026-01-20",
      "date_type": "hard",
      "archetype": "insider",
      "status": "tracking",
      "notes": "Director purchased 11.6k shares (~$4M). Confirmed cluster activity.",
      "linked_idea": null,
      "source": "Zacks, OpenInsider",
      "discovered_date": "2026-01-22"
    },
    {
      "id": "EVT-2026-069",
      "type": "insider",
      "ticker": "MSTR",
      "catalyst": "Insider buying cluster: MicroStrategy",
      "date": "2026-01-20",
      "date_type": "hard",
      "archetype": "insider",
      "status": "tracking",
      "notes": "Director purchased 5k shares (~$800k). High sentiment indicator.",
      "linked_idea": null,
      "source": "Zacks, OpenInsider",
      "discovered_date": "2026-01-22"
    },
    {
      "id": "EVT-2026-070",
      "type": "insider",
      "ticker": "SPT",
      "catalyst": "Insider buying cluster: Sprout Social",
      "date": "2026-01-20",
      "date_type": "hard",
      "archetype": "insider",
      "status": "tracking",
      "notes": "Cluster buy noted on OpenInsider Jan 20, 2026.",
      "linked_idea": null,
      "source": "OpenInsider",
      "discovered_date": "2026-01-22"
    }
  ]
}